HRP20150487T1 - Kompozicije za primjenu u lijeäśenju virusnih infekcija - Google Patents

Kompozicije za primjenu u lijeäśenju virusnih infekcija Download PDF

Info

Publication number
HRP20150487T1
HRP20150487T1 HRP20150487TT HRP20150487T HRP20150487T1 HR P20150487 T1 HRP20150487 T1 HR P20150487T1 HR P20150487T T HRP20150487T T HR P20150487TT HR P20150487 T HRP20150487 T HR P20150487T HR P20150487 T1 HRP20150487 T1 HR P20150487T1
Authority
HR
Croatia
Prior art keywords
virus
influenza
compound
group
use according
Prior art date
Application number
HRP20150487TT
Other languages
English (en)
Croatian (hr)
Inventor
Shanta Bantia
Pravin L. Kotian
Yarlagadda S. Babu
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of HRP20150487T1 publication Critical patent/HRP20150487T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20150487TT 2010-10-15 2011-10-14 Kompozicije za primjenu u lijeäśenju virusnih infekcija HRP20150487T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39352210P 2010-10-15 2010-10-15
US201161492054P 2011-06-01 2011-06-01
EP11833515.7A EP2627334B1 (en) 2010-10-15 2011-10-14 Compositions for use in the treatment of viral infections
PCT/US2011/056421 WO2012051570A1 (en) 2010-10-15 2011-10-14 Methods and compositions for inhibition of polymerase

Publications (1)

Publication Number Publication Date
HRP20150487T1 true HRP20150487T1 (hr) 2015-08-28

Family

ID=45938737

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150487TT HRP20150487T1 (hr) 2010-10-15 2011-10-14 Kompozicije za primjenu u lijeäśenju virusnih infekcija
HRP20180220TT HRP20180220T1 (hr) 2010-10-15 2018-02-06 Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20180220TT HRP20180220T1 (hr) 2010-10-15 2018-02-06 Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija

Country Status (23)

Country Link
US (6) US20130331404A1 (OSRAM)
EP (3) EP2898885B1 (OSRAM)
JP (2) JP5902698B2 (OSRAM)
KR (1) KR101850925B1 (OSRAM)
CN (1) CN103429245B (OSRAM)
AU (2) AU2011315902B2 (OSRAM)
BR (1) BR112013009029B1 (OSRAM)
CA (1) CA2813783C (OSRAM)
CY (1) CY1119880T1 (OSRAM)
DK (2) DK2627334T3 (OSRAM)
ES (2) ES2536831T3 (OSRAM)
HR (2) HRP20150487T1 (OSRAM)
HU (1) HUE036387T2 (OSRAM)
IL (1) IL225672B (OSRAM)
LT (1) LT2898885T (OSRAM)
MX (1) MX348759B (OSRAM)
PL (2) PL2627334T3 (OSRAM)
PT (2) PT2627334E (OSRAM)
RS (2) RS56870B1 (OSRAM)
RU (3) RU2599013C2 (OSRAM)
SI (2) SI2627334T1 (OSRAM)
SM (2) SMT201800064T1 (OSRAM)
WO (1) WO2012051570A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130048T1 (hr) 2008-04-23 2013-02-28 Gilead Sciences, Inc. Karba-nukleozidni analozi za antivirusnu terapiju
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
MX348759B (es) * 2010-10-15 2017-06-28 Biocryst Pharm Inc Metodos y composiciones para inhibicion de polimerasa.
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
WO2014078778A2 (en) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CA2911424C (en) 2013-05-14 2021-11-30 Biocryst Pharmaceuticals, Inc. Anti-influenza imino-ribose pyrrolopyrimidine derivatives
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN104513249B (zh) * 2014-12-26 2016-08-31 苏州明锐医药科技有限公司 抗埃博拉病毒药物bcx4430的制备方法
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
WO2017155886A1 (en) 2016-03-06 2017-09-14 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of zika virus infection
DE102016002873A1 (de) 2016-03-09 2016-05-25 Heinz Kiefer Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021207386A1 (en) * 2020-04-07 2021-10-14 Biocryst Pharmaceuticals, Inc. Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US20240285557A1 (en) * 2021-06-25 2024-08-29 Industry Foundation Of Chonnam National University Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections
KR102871928B1 (ko) * 2021-06-25 2025-10-20 전남대학교 산학협력단 지방분해효소 억제제를 포함하는 rna 바이러스 감염증 예방 또는 치료용 약제학적 조성물
JP2024531898A (ja) 2021-08-17 2024-09-03 サウスウエスト リサーチ インスティテュート コロナウイルスに対する阻害剤
CN115925640B (zh) * 2021-08-23 2025-03-28 中国人民解放军军事科学院军事医学研究院 ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯及其制备方法和应用
US12552827B2 (en) 2022-01-21 2026-02-17 Biocryst Pharmaceuticals, Inc. Synthesis of an antiviral azasugar triphosphate
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体
CN118359622B (zh) * 2024-04-16 2025-08-26 上海陶术生物科技股份有限公司 加利司伟中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20050250728A1 (en) * 2002-05-23 2005-11-10 Shanta Bantia Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
WO2006002231A1 (en) * 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP2537520A1 (en) * 2005-03-29 2012-12-26 Biocryst Pharmaceuticals, Inc. Hepatics C therapies
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
CN101528749B (zh) 2006-09-07 2013-07-31 工业研究有限公司 核苷磷酸化酶和水解酶的无环胺抑制剂
EA016830B1 (ru) 2006-09-11 2012-07-30 Саузерн Рисерч Инститьют Азольные нуклеозиды и их применение в качестве ингибиторов вариальных рнк- и днк-полимераз
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
MX348759B (es) * 2010-10-15 2017-06-28 Biocryst Pharm Inc Metodos y composiciones para inhibicion de polimerasa.
CN103201260B (zh) 2010-11-11 2015-05-27 莱德克斯制药有限公司 药物衍生物
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral

Also Published As

Publication number Publication date
CN103429245A (zh) 2013-12-04
SMT201800064T1 (it) 2018-03-08
EP2627334B1 (en) 2015-04-29
RU2016134401A (ru) 2018-12-10
AU2017200471A1 (en) 2017-02-23
CA2813783A1 (en) 2012-04-19
RS54072B1 (sr) 2015-10-30
US20190374544A1 (en) 2019-12-12
RU2020111042A (ru) 2021-09-17
RU2599013C2 (ru) 2016-10-10
US20130331404A1 (en) 2013-12-12
PL2627334T3 (pl) 2015-08-31
CA2813783C (en) 2019-01-22
WO2012051570A1 (en) 2012-04-19
DK2627334T3 (en) 2015-05-18
BR112013009029A2 (en) 2018-06-19
US20180360836A1 (en) 2018-12-20
ES2657687T3 (es) 2018-03-06
HK1257363A1 (en) 2019-10-18
HK1212914A1 (en) 2016-06-24
IL225672A0 (en) 2013-06-27
US9492452B2 (en) 2016-11-15
MX2013003938A (es) 2013-07-05
CY1119880T1 (el) 2018-06-27
DK2898885T3 (en) 2018-02-05
RU2013121794A (ru) 2014-11-20
PT2898885T (pt) 2018-02-05
AU2017200471B2 (en) 2018-04-12
SI2898885T1 (en) 2018-03-30
CN103429245B (zh) 2016-10-05
MX348759B (es) 2017-06-28
PL2898885T3 (pl) 2018-04-30
US10022375B2 (en) 2018-07-17
JP5902698B2 (ja) 2016-04-13
US10420769B2 (en) 2019-09-24
BR112013009029B1 (pt) 2021-06-29
LT2898885T (lt) 2018-02-26
SI2627334T1 (sl) 2015-08-31
AU2011315902B2 (en) 2016-11-17
KR101850925B1 (ko) 2018-04-20
RU2718690C2 (ru) 2020-04-13
JP2013544788A (ja) 2013-12-19
RS56870B1 (sr) 2018-04-30
US20170042901A1 (en) 2017-02-16
EP2627334A4 (en) 2014-04-16
EP3345605A1 (en) 2018-07-11
EP2898885A1 (en) 2015-07-29
US11173159B2 (en) 2021-11-16
AU2011315902A1 (en) 2013-05-30
US20150051230A1 (en) 2015-02-19
US12508266B2 (en) 2025-12-30
HUE036387T2 (hu) 2018-07-30
JP2016135790A (ja) 2016-07-28
HRP20180220T1 (hr) 2018-03-09
US20220040190A1 (en) 2022-02-10
EP2898885B1 (en) 2017-11-22
SMT201500148B (it) 2015-09-07
EP2627334A1 (en) 2013-08-21
RU2016134401A3 (OSRAM) 2020-01-24
ES2536831T3 (es) 2015-05-29
KR20140040676A (ko) 2014-04-03
EP3345605B1 (en) 2019-11-20
IL225672B (en) 2019-02-28
PT2627334E (pt) 2015-07-07

Similar Documents

Publication Publication Date Title
HRP20180220T1 (hr) Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija
JP2013544788A5 (OSRAM)
JP2016504284A5 (OSRAM)
Leyssen et al. Molecular strategies to inhibit the replication of RNA viruses
IL277160B1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2015514772A5 (OSRAM)
NZ596014A (en) Dihydroorotate - dehydrogenase inhibitors as virostatic compounds
RU2020116571A (ru) N4-гидроксицитидин и производные и связанные с этим противовирусные применения
JP2021517132A5 (OSRAM)
JP2025508942A5 (OSRAM)
WO2007103111A3 (en) Antiviral drugs for treatment of arenavirus infection
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
ATE541844T1 (de) Antivirale verbindungen
WO2008147474A3 (en) Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
BRPI0814737B8 (pt) composição para o tratamento de hcv, e, uso de uma composição
BR112012008533A8 (pt) combinações de inibidores do vírus da hepatite c
JP2014530874A5 (OSRAM)
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
NZ597544A (en) Modified 4'-nucleosides as antiviral agents
PE20090228A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
PH12012502343A1 (en) Antiviral drugs for treatment or prevention of dengue infection
JP2013537905A5 (OSRAM)
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
HRP20200045T1 (hr) Metode sa oligonukleotidnim helatnim kompleksom
JP2010285436A5 (OSRAM)